COLUMBIA U. (US) —Treating people for depression after a heart attack could reduce the risk of death or another attack, new research shows.
Researchers completed a randomized controlled trial with 150 patients with elevated depressive symptoms two to six months after hospitalization for heart disease.
Patients were recruited from seven centers across the United States; 73 received six months of patient-preference depression care, and 77 received six months of depression care determined by their physician upon notification that the patient had elevated depressive symptoms.
The patient-preference group was given a choice of therapy or antidepressants, or both.
“We tried to help them really think through, what does it take to take a pill every day, what it takes to talk to a person about painful feelings and do homework. We then considered what would fit into their life,” says Karina Davidson, professor of behavioral medicine in medicine, cardiology, and psychiatry at Columbia University Medical Center.
“Every six to eight weeks, we revisited how their chosen treatment was working for them and helped them make adjustments based upon their feedback.”
Therapy in this study was given virtually (by phone or web-based) by two counselors to ensure that patients had access to clinicians of a similar skill set. The virtual therapy also helped connect patients with therapists at times that were most convenient for them.
“Maybe 8 p.m. at your home is the right time for you, but not 8 p.m. if you have to go to a clinic or hospital, wait half an hour, and then travel back home afterwards,” says Davidson, who is also director of the Center for Behavioral Cardiovascular Health.
As reported in JAMA Internal Medicine, the therapy used in the trial was problem-solving treatment (PST)—a practical, hands-on approach that asks patients to choose the problems in their life that they want to tackle and teaches them how to problem-solve. Patients were assigned homework to try the solutions and then returned to talk about what worked and what didn’t, and tackle the next problem.
“What we want to know is whether this kind of patient-preference, centralized, heart disease-specific depression care was feasible and effective, and whether it also has the tantalizing possibility of being cost-neutral within six months,” Davidson says.
The findings showed that depressive symptoms were reduced more in the patient-preference, centralized depression care group than in the group of patients receiving usual care.
At the start of the trial, patients had an average of 19 points on the Beck Depression Inventory (BDI) depression scale. At the end of the trial, BDI scores in the patient-preference group were significantly reduced, by an average of 3 to 6 points more than in the other group.
Getting below 10 on the BDI puts one in the normal range—and almost half of the group who received patient-preference, centralized treatment got down to the normal range, compared with only one-third of the usual-care group.
Running centralized depression care at seven sites nationwide was effective, suggesting that it is feasible to deliver depression care to those who do not have specialists in their area.
Overall, the total health care costs for the patient-preference depression treatment group was $325 less than for the usual-care group, even when factoring in the cost of therapy. And fewer hospitalizations were seen in the patient-preference group than in the usual-care group.
“We really wanted to know whether we can treat depressive symptoms in a large group of patients nationwide and if doing so ultimately lowers their risk of death or having another heart attack,” Davidson says.
“Routine management of depressive symptoms in heart disease patients has been poor and lacked an evidence base. With these results, which will help us understand what we can do to relieve the suffering of those who experience both disabling problems, we can now propose a large, national trial more effectively and efficiently.”
Researchers from Stony Brook University, University of Florida, Emory University, Yale University, McGill University, New York University, University of Montreal, and St. John’s University contributed to the study, which was supported in part by the National Institutes of Health.
Source: Columbia University